Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 192 от 222

Набира участници Фаза 2

Adaptive RadioTherapy for OroPharynx Cancer

Oropharynx Cancer Radiotherapy; Complications Radiotherapy Side Effect Dysphagia +1

This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.

Начало: 30.07.2021 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Canada Centre hospitalier de l'Université de Montréal (CHUM) NCT04901234

Набира участници

Zimmer Biomet Shoulder Arthroplasty PMCF

Shoulder Fractures Shoulder Arthritis Shoulder Osteoarthritis Shoulder Deformity +2

The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.

Начало: 28.07.2021 Край: 15.08.2033 Възраст: от 20 г. Лечение

Japan, New Zealand, United States Zimmer Biomet NCT04984291

Набира участници Фаза 1

Understanding Ketamine's Dissociative Effects (KD Study)

Epilepsy

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Начало: 26.07.2021 Край: 01.08.2028 Възраст: от 18 г.

United States Stanford University NCT04861051

Набира участници

Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID

Severe Combined Immunodeficiency Due to RAG1 Deficiency

This study is a prospective, non-randomized, open-label, two-centre phase I/II intervention study designed to treat children up to 24 months of age with RAG1-deficient SCID with an indication for allogeneic hematopoietic stem cell transplantation but lacking an HLA-matched donor. The study involves infusion of autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (hereafter called RAG1 LV CD34+ cells) in five patients with RAG1-deficient SCID.

Начало: 23.07.2021 Край: 31.12.2029 Възраст: 8–24 г. Лечение

Australia, Italy, Netherlands +4 Leiden University Medical Center NCT04797260

Набира участници Фаза 1/2

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Endometrial Neoplasms Ovarian Neoplasms +2

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.

Начало: 19.07.2021 Край: 01.04.2027 Възраст: от 18 г. Лечение

Australia, Canada, France +3 Eli Lilly and Company NCT04956640

Набира участници Фаза 3

The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial

Bleeding Post Cardiac Surgery Indication for Anticoagulation

The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.

Начало: 18.07.2021 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia, Canada, Germany Population Health Research Institute NCT04284839

Набира участници Фаза 1/2

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Adenocarcinoma of the Pancreas

This will be a phase I/II trial examining the safety and tolerability of pre-operative mFOLFIRINOX in combination with peri-operative oral hydroxychloroquine (FHQ) in the treatment of subjects with adenocarcinoma of the pancreas. Subjects will be staged prior to protocol entry by contrast-enhanced helical abdominal CT scan done using a pancreas mass protocol or EUS. Eligible subjects with biopsy-proven, resectable pancreatic adenocarcinoma without evidence of venous or arterial involvement on CT scan receive HCQ orally in combination with mFOLFIRINOX prior to surgery. Hydroxychloroquine will begin with the first dose of mFOLFIRINOX and continue for 2 weeks post-operatively. Three to six weeks after the last dose of mFOLFIRINOX, patients will undergo surgical exploration and pancreatectomy if technically feasible and all toxicities have resolved. Pathologic specimens will undergo detailed histopathologic and immunohistochemical evaluations with particular attention to the six surgical margins of resection: the bile duct margin (for Whipple specimens), the margin of pancreatic transection, the retroperitoneal margin, the proximal and distal duodenal margins (for Whipple specimens), and the portal vein margin along the pancreatic head (for Whipple specimens) or medial pancreas (for distal pancreatectomies). Tissue specimens will be stored at -80C for future correlative studies of autophagy and tumor response to protocol therapy. Ten to fourteen weeks following completion of successful surgical removal of their tumor, subjects will undergo repeat staging studies per standard of care. Subjects will pursue standard of care adjuvant therapy options at the discretion of their physician.

Начало: 16.07.2021 Край: 01.06.2030 Възраст: от 18 г.

United States West Virginia University NCT04911816

Набира участници

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Papillary Thyroid Cancer Pediatric Cancer Differentiated Thyroid Cancer

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.

Начало: 16.07.2021 Край: 01.02.2033

Australia, United States Children's Hospital of Philadelphia NCT05024929

Набира участници Фаза 3

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Myasthenia Gravis

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \[PD\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.

Начало: 15.07.2021 Край: 30.03.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +13 Janssen Research & Development, LLC NCT04951622

Набира участници Фаза 2

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Critical Illness Osteoporosis

The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission to intensive care for greater than 24 hours. 450 women aged 50 years or older and men aged 70 years or older, admitted to intensive care for greater than 24 hours will be recruited into the study from participating study centres.

Начало: 15.07.2021 Край: 28.02.2027 Възраст: от 50 г. Лечение

Australia, New Zealand Australian and New Zealand Intensive Care Research Cent NCT04608630

Набира участници Фаза 2

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Central Nervous System Nongerminomatous Germ Cell Tumor Choriocarcinoma Embryonal Carcinoma Immature Teratoma +6

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.

Начало: 13.07.2021 Край: 21.12.2029 Възраст: 3–29 г. Лечение

Australia, Canada, New Zealand +1 Children's Oncology Group NCT04684368

Набира участници Фаза 2

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone is a synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland), and is used with other drugs in the treatment of some types of cancer. Giving iberdomide with dexamethasone my improve time to progression to symptomatic myeloma with improved tolerability.

Начало: 09.07.2021 Край: 01.09.2029 Възраст: от 18 г.

United States Emory University NCT04776395

Набира участници

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

Liver Diseases Liver Cirrhosis Acute-On-Chronic Liver Failure Liver Transplant; Complications

Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.

Начало: 08.07.2021 Край: 31.12.2026 Възраст: 18–80 г.

Argentina, Australia, Belgium +21 European Foundation for Study of Chronic Liver Failure NCT04613921

Набира участници Фаза 4

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Atrial Fibrillation

Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others. Not only can it ruin one's life, but it can also be fatal. A stroke occurs when blood flow to the brain is blocked by a clot, depriving brain cells of oxygen. In people with atrial fibrillation, blood flow is sluggish in the top chambers of the heart, and blood clots can form there. When a piece of a clot breaks off, it can travel to the brain and cause a stroke. That's where blood thinners come in. Blood thinners, or anticoagulants, decrease the chances of blood clots forming in the heart, reducing the risk of stroke. Studies show that blood thinners are highly effective at reducing the risk of stroke by up to 95%. The conventional blood thinner is warfarin, taken by mouth. Warfarin requires regular blood tests to make sure a patient getting the correct dose. The patient also may have to avoid certain foods since the medication can interact with them. Newer blood thinners, known as direct-oral anticoagulants (DOACs) are available, which do not require regular blood tests and do not interact with foods. Two of the new blood thinners are called rivaroxaban and apixaban. Like warfarin, they can be taken by mouth, and studies have shown them to be as effective as warfarin. Both rivaroxaban and apixaban have been approved for stroke prevention in AF by Health Canada. However, there have been no direct head-to-head comparisons of these two anticoagulants, meaning comparative safety data is not available. Increasing use of DOACs for stroke prevention in AF and patient values around bleeding highlight the need for a comparison trial to ensure patients receive the anticoagulant with the greatest balance of benefit to potential harm. The trial is to assess bleeding rates and superiority of using apixaban versus rivaroxaban in patients with non-valvular atrial fibrillation.

Начало: 06.07.2021 Край: 31.12.2027 Възраст: от 18 г.

Canada Ottawa Hospital Research Institute NCT04642430

Набира участници Фаза 1

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma Recurrent Platinum-Resistant Ovarian Carcinoma

This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer.

Начало: 02.07.2021 Край: 01.11.2026 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT04633239

Набира участници

HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Mitral Regurgitation

Feasibility, safety and performance of the HighLife CLARITY TSMV and its delivery system

Начало: 01.07.2021 Край: 01.02.2031 Възраст: от 18 г. Лечение

Australia, Belgium, France +3 HighLife SAS NCT04888247

Набира участници Фаза 2

Antidepressant Effects of Nitrous Oxide

Major Depressive Disorder Treatment Resistant Depression

To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.

Начало: 30.06.2021 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, United States University of Chicago NCT05357040

Набира участници

Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System

Pulmonary Embolism

The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).

Начало: 25.06.2021 Край: 01.02.2028 Възраст: от 18 г.

Australia, Brazil, Germany +7 Penumbra Inc. NCT04798261

Набира участници Фаза 3

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Начало: 23.06.2021 Край: 01.07.2041 Възраст: 50–70 г.

Canada, Hong Kong, Japan +1 NRG Oncology NCT04852887

Набира участници Фаза 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma Pancreatic Adenosquamous Carcinoma Pancreatic Squamous Cell Carcinoma Resectable Pancreatic Acinar Cell Carcinoma +3

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Начало: 22.06.2021 Край: 31.10.2027 Възраст: от 18 г.

Israel, Puerto Rico, United States National Cancer Institute (NCI) NCT04858334

1 … 190 191 192 193 194 … 222